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Essentials
• In 2016 the SSC proposed definitions for effective
hemostasis in management of major bleeding.
• To validate these definitions, we studied the use in three
large anticoagulant-reversal studies.
• Method agreement analysis and interobserver reliability
showed at least acceptable agreement.
• Recommendations were made, advising use of the defi-
nition in hemostatic effectiveness studies.
Summary. Introduction: In 2016 the Scientific and Stan-
dardization Subcommittee (SSC) on Control of Anticoag-
ulation of the International Society on Thrombosis and
Haemostasis (ISTH) proposed criteria to evaluate the
effectiveness of anticoagulant reversal in major bleeding
management. Testing and validation of these criteria are
required. Objective: To investigate the method agreement,
interobserver reliability and applicability of the ISTH pro-
posed definitions for hemostatic effectiveness. Methods:
Patient data from three anticoagulant-antidote studies
were used for hemostatic effectiveness assessment using
the ISTH-proposed definitions and clinical opinion. For
every patient a case document was produced. For each
cohort, four adjudicators were asked to assess the hemo-
static effectiveness independently on a case-by-case basis.
Agreement between the two methods of hemostatic effec-
tiveness assessment was calculated using Cohen’s kappa
(j), with a calculated sample size of at least 73 cases. Re-
sults: The full dataset consisted of 116 cases, resulting in
464 assessments. Method agreement in outcome was
observed in 364 of 464 assessments (78.5%), resulting in j
of 0.634 (95% CI: 0.575–0.694), or “substantial agree-
ment.” Interobserver reliability analysis of the proposed
definitions computed an overall agreement of 54.2% with
j of 0.312 (“fair agreement”). Discussion: Method agree-
ment analysis shows that the conclusions drawn using the
ISTH definitions have “substantial agreement” with clini-
cal opinion. Interobserver reliability analysis demonstrated
acceptable agreement. In-depth analysis provided minor
opportunities for further improvement and correct appli-
cation of the definition. The definition is recommended to
be used in all future studies evaluating hemostatic effec-
tiveness, taking the suggested recommendations into
account.
Keywords: anticoagulants; bleeding; hemostasis; outcome
assessment; prothrombin complex concentrates.
Introduction
A common challenge for studies investigating the hemo-
static effectiveness of an intervention in bleeding patients
on anticoagulants consists of defining and measuring clin-
ical outcome. In the absence of a standardized definition,
studies evaluating the effect of antidotes for oral antico-
agulants often seek to define surrogate laboratory
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parameters such as improvement/normalization of inter-
national normalized ratio (INR), diluted thrombin time,
or anti-factor Xa activity as primary measurement of
anticoagulation reversal. Whenever clinical outcome is
evaluated, it is usually with ad hoc formulated definitions
assessing hemostatic effectiveness.
Recent landmark studies on reversal of anticoagulants
highlight this problem. In 2013 Sarode et al. reported in a
study evaluating prothrombin complex concentrate (PCC)
a definition for hemostatic effectiveness formulated in
consultation with the US Food and Drug Administration
(FDA) [1]. With input from the regulatory authority they
designed a rational definition for hemostatic effectiveness.
The study evaluating idarucizumab by Pollack et al. in
2017 reported clinical outcome by assessment of the
extent of bleeding and hemodynamic stability at multiple
time points [2]. The third study of note is the andex-
anet alfa study by Connolly et al. in 2016, which reported
the use of an adapted version of the Sarode criteria [3].
The lack of standardized definitions introduces bias
and hampers comparison between treatments and studies.
This was first acknowledged in a systematic review com-
paring PCC dosing strategies in 2015 [4], which prompted
the Scientific and Standardization Subcommittee (SSC)
on Control of Anticoagulation of the International Soci-
ety on Thrombosis and Haemostasis (ISTH) to approach
the problem. As a result, definitions were proposed for
assessment of effectiveness of major bleeding management
in 2016 [5], prepared by a working group consisting of
the same authors as the current project.
The recently proposed definitions formulate, for each
specific bleeding type, criteria that should be met in regard
to the hemostatic treatment outcome as “effective.” A sche-
matic summary of the proposed criteria per bleeding type is
given in Fig. 1; full details can be found in [5].
However, the preceding definitions only represent an
expert consensus so far, and testing and validation of
these criteria are therefore required. Agreement should be
determined between the new method and the current clin-
ical gold standard, which is the opinion of the physician
involved in the bleeding management at the bedside. Fur-
thermore, interobserver reliability should be determined
and limitations in applicability of the new method need
to be identified and resolved.
The current study seeks to test and validate the pro-
posed definitions to increase understanding of the feasibil-
ity and limitations of this assessment tool and ultimately
provide a justification for use in future clinical trials, but
also in clinical practice.
Methods
Aims
The primary aim for this study was to investigate the method
agreement of hemostatic effectiveness assessment using the
ISTH-proposed definitions and clinical opinion. Further-
more, interobserver variability of the ISTH-proposed defini-
tions was analyzed and applicability of the proposed criteria
was studied.
Cases and adjudication
For hemostatic effectiveness assessments, we used
patient data from three anticoagulant-reversal studies or
registries that the authors had access to. The studies
were regarded as three separate cohorts throughout the
current project, each with its own specific characteris-
tics. A summary of important details on the three









Cessation of visible 
bleed within 4 hours
Hemoglobin level is 
stable at 48 h 
(≤ 10% reduction)
Pain and swelling is 
not worsened within 
24 hours
Hematoma volume in 
follow-up CT (t = 12 h) is
max. 35% increased
GOS-E (or any vali-
dated scoring system): 
no deterioration at 
t = 24 h
At 48 h:
no need for 





either avoided or 
carried out with 
normal blood loss
Fig. 1. Simplified schematic representation of ISTH-proposed definitions for effective hemostasis in management of major bleeding. GOS-E,
Extended Glasgow Outcome Scale.
© 2019 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Throm-
bosis and Haemostasis.
500 R. A. Abdoellakhan et al
were available at the time of this study from the under-
lying ongoing projects of cohorts A and B were
included, whereas for cohort C data collection stopped
after including the first 57 consecutive patients, meeting
sufficient sample size.
For every patient within these cohorts a case document
was produced. For cohorts A and B, this included admis-
sion and discharge notes, all progress notes, laboratory
data, transfusion data, medication log, and imaging
reports. For cohort C case summaries were composed,
describing admission, progress, imaging and discharge
notes, and relevant laboratory and transfusion data.
Adjudicators were blinded to details of the hemostatic
agent of interest when the original trial intervened in dose
or regimen of that hemostatic agent.
For each cohort, four adjudicators were asked to assess
the hemostatic effectiveness on a case-by-case basis inde-
pendently. Two of four adjudicators were part of the SSC
working group that had formulated the ISTH criteria,
representing the “working group” observers. The other
two were physicians experienced in the assessment of
bleeding, but not previously involved with the ISTH
criteria, representing “na€ıve” observers.
A case assessment form was developed in which the
adjudicator was first asked to assess the hemostatic effec-
tiveness according to the adjudicator’s clinical opinion,
the current gold standard method in clinical practice. Sub-
sequently the adjudicator was asked to reassess the hemo-
static effectiveness using the new ISTH-proposed criteria.
Of note, a necessary adjustment, which was erroneously
missing in the published proposed definitions [5], was made
to the definition beforehand: it was allowed to replace the
Extended Glasgow Outcome Scale (GOS-E) with other val-
idated scoring systems to assess neurologic outcome in
intracranial hemorrhage (ICH). For this specific project,
we chose to allow the Glasgow Coma Scale (GCS) to be
used as an alternative when GOS-E was missing. In case of
intraobserver discrepancy between clinical opinion and
assessment using the ISTH definition, or in case of non-
assessability, a possible explanation was requested.
Analysis and statistics
Sample size calculation was based on the Cohen’s j test
used for method agreement analysis in the full dataset,
determining the chance-adjusted agreement between the
two methods of hemostatic effectiveness assessment [12].
A previously described approach was used to calculate
the sample size [13]. Assumptions for calculation were
made, based on three possible outcomes (i.e., effective,
non-effective, and not assessable) and four adjudicators
for every case [14]. Anticipated j was set at 0.8, maxi-
mum confidence interval width at 0.2, an estimated pro-
portion of categories at 0.2, 0.3, and 0.5, with a = 0.05
and b = 0.20. This resulted in a minimum sample size of
73 cases to be assessed by four observers, totaling 292
assessments.
Interobserver reliability of the four observers was
calculated using the free marginal Fleiss’ j statistic to
determine multiple (>2) rater chance-adjusted agreement
[15–17]. A subgroup analysis for interobserver agreement
was performed to exclude bias introduced by non-assessa-
ble cases, by excluding cases that one or more of the
observers had rated as not assessable according to the
ISTH definitions.
The applicability of the definition consisted of analysis
of (i) interobserver agreement in bleeding type, (ii) out-
come assessment analysis per bleeding type and (iii) in-
depth analysis of non-assessability of cases. For analysis
of interobserver agreement in bleeding type, Fleiss’ j
statistic was used. Cases with discrepancy in bleeding type
between adjudicators were analyzed for consequences in
hemostatic effectiveness outcome.
For in-depth analysis of the non-assessability of cases,
correct bleeding types were retrospectively (after comple-
tion of all assessments) assigned to every case by two
members of the working group, with the help of a third if
no consensus could be reached. Then cases were catego-
rized per correct bleeding type and analyzed for propor-
tion of assessments with corresponding bleeding type
assignment by the adjudicators. Finally, the assessments
with corresponding bleeding type assignment that con-
cluded hemostatic effectiveness to be non-assessable were
analyzed for frequency and reason for non-assessability.
Each analysis was performed on the full dataset at first
and then, where applicable, for each cohort separately.
Kappa values were interpreted using the definition of
Landis and Koch; see Table 2 [18].
Results
The full dataset consisted of 116 cases, resulting in 464
assessments. In cohort A, four observers adjudicated 40
consecutive cases, totaling 160 assessments; cohort B
Table 1 Cohort characteristics of cases included
Cohort A [6] Cohort B [7–10] Cohort C [11]
Cases (n) 40 19 57

















Country The Netherlands Germany Canada
4F-PCC, 4-factor prothrombin complex concentrate; NOAC, non-
vitamin K antagonist oral anticoagulant; RCT, randomized con-
trolled trial; VKA, vitamin K antagonist.
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totaled 76 assessments for 19 cases, and cohort C 228
assessments for 57 cases.
Method agreement analysis
Agreement in outcome between methods in the full data-
set was observed in 364 of 464 cases (78.5%), resulting in
a Cohen’s j of 0.634 (95% CI: 0.575–0.694), or “substan-
tial agreement.” In detail, j in cohort A was 0.669 (95%
CI: 0.553–0.785), in cohort B 0.467 (95% CI: 0.322–
0.611), and in cohort C 0.657 (95% CI: 0.577–0.737). A
sensitivity analysis was performed limited to cohorts with
hemostatic effectiveness in some way predefined, i.e.,
cohorts A and C, totaling 97 cases. This produced a
Cohen’s j of 0.670 (95% CI: 0.553–0.785), or “substantial
agreement,” confirming the agreement found in the full
dataset.
The sensitivity and specificity of assessment using the
ISTH definition in the full dataset were 74.3% and
86.9%. Details of sensitivity and specificity per cohort are
displayed in Table 3.
Interobserver reliability
Interobserver reliability analysis of the proposed defini-
tions on the full dataset computed an overall agree-
ment of 54.2% with a Fleiss free marginal chance-
corrected agreement j of 0.312 (“fair agreement”). For
comparison purposes, interobserver reliability for
assessment based on adjudicator’s clinical opinion had
an agreement of 69.0% with j 0.534 (“good agree-
ment”). Working group observers produced a slightly
better j when using the proposed definitions compared
to na€ıve observers upon stratification (0.392 and 0.276,
respectively). Finally, when focusing only on cohorts
with hemostatic effectiveness predefined (cohorts A
and C), agreement was demonstrated to be slightly
better than in the full dataset, with agreement being
57.2% and j being 0.358 (“fair agreement”). Kappa
values stratified per cohort and observers are displayed
in Table 4.
For the subgroup analysis, 7 cases in cohort A (18%)
were rated not assessable by at least one of the observers
when using the ISTH-proposed definitions. In the same
manner 16 cases (84%) were not assessable in cohort B
and 32 cases (56%) in cohort C. Consequently, j was
0.333 in cohort A and 0.620 in cohort C, while for cohort
B j was not calculated because of a low number of
remaining cases. Thirty-seven of the total of 55 cases
(67%) that were not assessable when using the ISTH-pro-
posed definitions were also not assessable by the
adjudicator’s clinical opinion.
Applicability of the definition
An in-depth analysis per bleeding type was performed, in
which further analysis of the use and non-assessability of
the ISTH definition was performed. For this analysis
only, two members of the working group assigned correct
bleeding types to the cases in retrospect. Consensus was
reached for all cases.
Figure 2 displays the distribution of assessed outcomes
specified per bleeding type. Here the absence of false posi-
tives is demonstrated, except in two assessments in the
non-visible bleed type category (1%). Both were caused
by evident adjudicator error, i.e., severe ongoing blood
loss in one case and a recurrent bleed in the other, both
of which should have resulted in non-effective hemostasis
if ISTH-proposed definitions were followed correctly.
False negative rates can also be read from Fig. 2 to be
less than 9% in each bleeding type category except in
musculoskeletal bleeds, in which the rate was 17%. Most
common reasons for false negatives were found to be ces-
sation of bleeding according to clinical opinion, but not
Table 2 Interpretation of kappa [18]
Kappa statistic Agreement





0.81–1.00 Almost perfect agreement
Table 3 Intraobserver, intermethod agreement expressed in percent-
age agreement and Cohen’s kappa of hemostatic effectiveness deter-
mination using the ISTH definitions and clinical opinion. Sensitivity
and specificity of the ISTH definition are also displayed

























Sensitivity 74.3 83.3 55.3 72.9
Specificity 86.9 94.1 68.8 87.5
CI, confidence interval.
Table 4 Interobserver reliability, expressed as % overall agreement









Agreement (%) 54.2% 60.8% 38.6% 54.7%
Kappa 0.312 0.413 0.079 0.320
Kappa (naive
observers only)
0.276 0.363 0.211 0.237
Kappa (working group
observers only)
0.392 0.438 0.368 0.368
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meeting the ISTH-proposed criteria, in 50% and adjudi-
cator error in 25%.
Table 5 gives an overview of the cases and their
assessed bleeding types by the adjudicators, specified per
correct bleeding type as assigned by the working group in
retrospect. Furthermore, frequencies and reasons for non-
assessability when using the ISTH definition are given for
cases in which the assessed bleeding type was identical to
the correct bleeding type. Most non-assessable cases origi-
nated from cohorts B and C. Most discrepancy between
bleeding type as assessed by the adjudicator and the cor-
rect bleeding type was seen in the non-visible and visible
bleeding types.
Interobserver agreement in bleeding type
Kappa values for interobserver agreement in bleeding
type for cohorts A, B, and C were 0.606, 0.889, and
0.960, respectively. Full agreement between all observers
was reached in 19/40 cases in cohort A, in 15/19 cases of
cohort B, and in 53/57 cases in cohort C. Nearly all cases
(23 of 25) that were assigned more than one bleeding type
by observers were due to discrepancy in the discrimina-
tion between visible and non-visible bleeding types. These
were 17 GI bleeds, 1 epistaxis combined with GI bleeding,
1 hematuria, 1 renal bleeding, 1 intraabdominal bleed, 1
vaginal bleed, and 1 case of hemoptysis.
In 10 of 23 cases that were assigned non-visible and vis-
ible bleed types, the bleed type assignment had no conse-
quences for the hemostatic effectiveness conclusion. In 4
cases, however, there were consequences for the conclu-
sion, meaning that bleeding type specific questions (i.e.,
hemoglobin drop at 48 h for non-visible bleeds or cessa-
tion at 4 h for visible bleeds) resulted in contrasting
answers, leading to different conclusions in outcome. For
the remaining cases it was inconclusive whether bleeding
type assignment had consequences for the outcome.
Discussion
This study reports on the applicability and reliability of















































































Fig. 2. Contingency tables of hemostatic effectiveness assessment by clinical opinion and by ISTH-proposed definitions (ISTH), specified per
bleeding type. (A) Non visible bleeding, (B) visible bleeding, (C) musculoskeletal bleeding, (D) intracranial bleeding.
Table 5 Bleeding type assessment distribution of cases categorized per correct bleeding type and frequencies with reasons of non-assessable
cases when using the ISTH-proposed definition for hemostatic effectiveness assessment
Cases (n) Assessments (n) Assessed bleeding type (n)
Correctly assessed bleeding type and ISTH
not assessable (n)




• Follow-up CT not assessable: 55
• GOS-E & GCS not assessable: 60




• Pain & swelling not assessable: 7
• In cohort B & C: 6




• Hemoglobin not assessable: 22
• In cohort B & C: 19
Visible 9 36 Visible: 32
Non-visible: 4
6 (8%)*
• Cessation not assessable: 6
• In cohort B & C: 6
GCS, Glasgow Coma Scale; GOS-E, Extended Glasgow Outcome Scale; ICH, intracranial hemorrhage. *For non-visible and visible bleeds,
assessments were pooled because of large interobserver variability in bleeding type.
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hemostatic effectiveness of anticoagulant reversal. The
results of the method agreement analysis show that the
conclusions drawn using the ISTH definitions have, to
our expectations, “substantial agreement” with clinical
opinion. This implies that the systematic, predefined
approach of the proposed definitions has face value; it
produces a similar and thereby acceptable outcome to
clinical opinion.
In-depth analysis of the cases demonstrated the near-
absence of false positives for all bleeding types. False neg-
atives were for all bleed types below 9% except for mus-
culoskeletal bleeds, in which a rate of 17% was found.
The main reasons for false negatives were adjudicator
error in 25% and, more importantly, clinically evident
cessation of bleeding without meeting the bleeding-type
specific criteria in 50%.
The presence of false negatives was, however, expected
considering the conservative nature of the definition. In
light of this, compared to the total number of assess-
ments, a false negative rate of 7%, with approximately a
quarter due to adjudicator error, can be regarded as
acceptable as broadening of the criteria will likely lead to
a higher number of false positives. For musculoskeletal
bleeds, however, broadening the criterion to “no worsen-
ing of pain and swelling” instead of “pain and swelling”
would improve face value. The assessment of pain and
swelling should furthermore be predefined in the protocol
of prospective studies. The false negative rates caused by
adjudicator error could be resolved by instruction of the
adjudicator and the use of more than one adjudicator.
Further incentive for adjustment of criteria arose from
analysis of non-assessable cases. The cases rated most fre-
quently as not assessable were from cohorts B and C, in
which the definition was applied after data collection, i.e.,
post hoc. For cohort A, which was predefined to collect
data relevant to the definition, the parameters required by
the definition seemed feasible. In this predefined cohort
ICH was, however, excluded so the question remains how
feasible repeat CT and/or GOS-E or GCS scoring is for
this type of cohort. In the post hoc setting it appears that
the specifically required parameters at fixed time points,
on which the definition depends, are often lacking. Conse-
quently, in prospective data collection, the time points for
repeat CT and/or GOS-E or GCS should be predefined in
study protocols.
Another difference in application of the definitions
between predefined and post hoc cohorts was identified in
the interobserver reliability analysis. Although “fair agree-
ment” for the proposed definition in the full dataset is
acceptable, it suggests that the systematic and predefined
approach still leaves some room for interpretation and dis-
agreement between adjudicators. Stratification between
cohorts clarified that this is especially the case if the data
required by the definition is missing or not obvious enough.
As a result interobserver reliability in cohort A, in which
assessment criteria were predefined, showed ‘good
agreement’, while post hoc cohorts B and C demonstrated
only “slight agreement” and “fair agreement.”
Last, interobserver agreement in bleeding type revealed
that there is considerable variation in defining a bleeding
to be visible or non-visible. This was also concluded from
the in-depth analysis per bleeding type in Table 4. While
it was obvious to classify intracranial bleeds and muscu-
loskeletal bleeds as such correctly, it appeared to be less
obvious to identify the rest of the bleeds to either visible
or non-visible, which was especially common in bleedings
that usually receive endoscopic diagnosis and/or treat-
ment: gastrointestinal bleeding, hemoptysis, and hema-
turia. For standardization purposes, the current ISTH
definition could provide more clarification on how to cat-
egorize such bleeding events as either visible or non-visi-
ble bleeds.
In the spirit of the development of definitions, visible
bleeds were meant to be classified as such when the focus
of the bleeding is directly visible (e.g., skin surface, visible
mucosal bleed [oral/nose/anal]) or is located in a com-
partment in which blood cannot be occult for longer peri-
ods (e.g., hemoptysis, hematuria). Bleeds with non-visible
focus that cannot be classified as musculoskeletal or
intracranial bleeds (e.g., occult hemoglobin/blood loss) or
bleeds located in compartments that could store blood for
longer periods, should be classified as non-visible bleeds
(e.g., GI bleeds, intraabdominal bleeds, parenchymal
bleed). For these bleeding events, the course of hemoglo-
bin levels is the most appropriate clinical way to assess
hemostatic effectiveness during follow-up. Exact prede-
fined guidance for data collection is recommended for
future prospective studies.
The current work was performed with a large number
of observers with diverse expertise and experience with
these definitions. This benefited the applicability of study
results with respect to adjudicators. The use of multiple
cohorts stemming from different studies with unique char-
acteristics, focusing on hemostatic interventions for vari-
ous anticoagulants, contributed even further to the
applicability of results in general. A disadvantage of the
data was the lack of ICH cases in a predefined setting
(cohort A).
Based on these validation results, the current ISTH def-
initions can be recommended to be used as standard for
assessment of hemostatic effectiveness. On the basis of in-
depth analysis, we recommend taking the following into
account when using the definition:
• For prospective studies, design the study to promote
the collection of parameters at the specified time points
as required by the ISTH definitions.
• Use two or more adjudicators and have cases adjudi-
cated independently with consensus forming after dis-
cussion.
• Make sure that adjudicators read and understand defi-
nitions and assessment criteria.
© 2019 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Throm-
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• For the intracranial bleeding type, it is advised (as was
erroneously missing in the first publication) to allow
replacement of GOS-E with any validated scoring sys-
tem to assess neurologic outcome if GOS-E is not rou-
tinely collected (especially in post hoc settings). We
would recommend GCS as a valid alternative.
• Prespecify precisely the categorization of non-visible
and visible bleeds.
Conclusions
In conclusion, the ISTH-proposed definitions for effec-
tive hemostasis in management of major bleeding were
validated for use in datasets containing the parameters
needed to evaluate the criteria of the definition. The
definition demonstrated good method agreement and
fair interobserver agreement. In-depth analysis provided
recommendations to improve application of these defini-
tions further. These definitions are recommended to be
used as standard for assessing hemostatic effectiveness
in all future studies evaluating management of major
bleeding, taking the formulated recommendations into
account.
Addendum
R. A. Abdoellakhan, J. Beyer-Westendorf, S. Schulman,
R. Sarode, K. Meijer, and N. Khorsand were involved in
the study design. Data were collected by J. Beyer-Westen-
dorf, S. Schulman, K. Meijer, and N. Khorsand. R.A.
Abdoellakhan, K. Meijer, and N. Khorsand analyzed the
data and wrote the concept version of the manuscript. All
authors reviewed, contributed to, and approved the final
version of the manuscript.
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